|
|
Post by JHam on Jul 16, 2020 17:53:30 GMT
Got my average down to $12.84. Take my money...   |
|
|
|
Post by JHam on Jul 17, 2020 4:20:50 GMT
I averaged down once again before the closing bell. Working that cost basis down slowly but surely, now at $12.50. Here is a very good interview with the CFO from January on how they are very protective of their capital structure. I would have liked this article a lot more if I had read before they gave the banks a 30%+ discount with their offering. That said, there weren't any warrants attached, or any preferred stock issued. It was a clean one time deal and I think it won't have too much of a negative impact in the long haul. The share count is still very low, about 13.1M shares out with a 5-6M float: www.cfodive.com/news/INmune-Bio-simplified-biopharma-cap-structure/570538/CFO touts simplified biopharma cap structure“If you’ve got more than common stock and debt outstanding, and covenants on the debt, and covenants on preferred stock, and if you have A, B, C, D, E and F preferred stock, and you have different conversion rights, different voting rights, and some have warrants on top of that, and the warrants have special provisions in them that allow the investors who hold those warrants to do special [things], you risk [your ability] to control your destiny,” Moss said. |
|
|
|
Post by JHam on Jul 17, 2020 5:38:22 GMT
A new article published out of Korea that supports INMB's approach to treating COVID-19: m.koreabiomed.com/news/articleView.html?idxno=8748Joint research team finds cause for ‘cytokine storm’
Shim Hyun-tai Published 2020.07.14 14:59 Updated 2020.07.14 14:59 The Korea Advanced Institute of Science and Technology said Monday that a joint team of researchers have what causes the hyper-inflammatory response in severe Covid-19 patients. The hyper-inflammatory response, often called the “cytokine storm,” is a symptom, in which the cytokine, an immune substance, is secreted excessively and attacks healthy cells. Cytokine storm is known to cause severe Covid-19. Still, the hyper-inflammatory response's specific cause had been unknown, resulting in difficulties in treating Covid-19 patients. A joint research team of KAIST and university hospitals has found that interferon triggers severe COVID-19 symptoms. From left are KAIST Professor Shin Eui-cheol and researchers Lee Jeong-seok and Park Seong-wan. (KAIST) The rapidly spreading Covid-19 virus has infected more than 13 million people worldwide and claimed more than 500,000 lives. The joint research team, composed of Korea Advanced Institute of Science (KAIST) and Technology, Asan Medical Center, Severance Hospital, and Chungbuk National University Hospital, analyzed severe and mild Covid-19 patients' samples. The result showed that tumor necrosis factor (TNF) and interleukin-1 (IL-1), which are inflammatory cytokines, were commonly observed in the immune cells of Covid-19 patients regardless of the degree of symptoms. According to a comparative analysis of severe and mild patients, the cytokine response called interferon was peculiarly strong in severe Covid-19 patients. Interferon is a type of cytokine secreted when its host cell is infected by pathogens such as viruses, bacteria, and parasites, or with the presence of cancer cells. Generally, interferon type 1 produced by infected cells helps surrounding cells to exhibit antiviral defense against infection. The research team said that non-specific anti-inflammatory drugs such as steroids could alleviate hyper-inflammatory response in patients with severe Covid-19. However, the study results could provide a new treatment that targets interferon. "We launched the study urgently to solve the medical problems of Covid-19 patients. Thanks to the support from Asan Medical Center, Severance Hospital, and Chungbuk National University Hospital, we could finish the study in three months," KAIST researcher Lee Jeong-seok said. KAIST will continue to study new immune mechanisms and personalized anti-inflammatory drugs to increase the survival rate of severe Covid-19 patients, he added. Their study, “Immunophenotyping of COVID-19 and Influenza Highlights the Role of Type 1 Interferons in Development of Severe COVID-19,” was published on the July 10 edition of the journal, Science Immunology. shim531@docdocdoc.co.kr |
|
|
|
Post by JHam on Jul 17, 2020 14:21:14 GMT
Averaged down again at $11.25. This could reverse (already is at the moment) and started heading back up. I have a solid position but am looking to double it in the next few weeks.
|
|
|
|
Post by selluwud on Jul 17, 2020 14:38:06 GMT
Averaged down again at $11.25. This could reverse (already is at the moment) and started heading back up. I have a solid position but am looking to double it in the next few weeks. I missed adding my 2nd half as I was looking for something closer to the raise price. Happy with my 1st half buy and will add if the opportunity arises. |
|
|
|
Post by JHam on Jul 17, 2020 14:50:34 GMT
Averaged down again at $11.25. This could reverse (already is at the moment) and started heading back up. I have a solid position but am looking to double it in the next few weeks. I missed adding my 2nd half as I was looking for something closer to the raise price. Happy with my 1st half buy and will add if the opportunity arises. Hit $12.87 for a split second. I don’t mind adding below $15. Average is now $12.17, but not sure I’ll be able to get it below $11 now. |
|
|
|
Post by selluwud on Jul 17, 2020 17:19:28 GMT
I missed adding my 2nd half as I was looking for something closer to the raise price. Happy with my 1st half buy and will add if the opportunity arises. Hit $12.87 for a split second. I don’t mind adding below $15. Average is now $12.17, but not sure I’ll be able to get it below $11 now. I got my 2nd half order to execute and will have a 11.85 average, let her rip. |
|
|
|
Post by JHam on Jul 20, 2020 14:25:47 GMT
Happy to see this one in the move again today but a little bummed I couldn’t add more.
|
|
|
|
Post by JHam on Jul 20, 2020 17:12:34 GMT
On the move big time now.
|
|
|
|
Post by JHam on Jul 20, 2020 17:31:34 GMT
|
|
|
|
Post by selluwud on Jul 20, 2020 19:40:16 GMT
Crazy man, this must be the cure. Let'er rip.
|
|
|
|
Post by JHam on Jul 20, 2020 19:46:16 GMT
Crazy man, this must be the cure. Let'er rip. I’m trying to get in one last buy. Hoping for mid $13s. |
|
|
|
Post by JHam on Jul 23, 2020 15:38:17 GMT
|
|
|
|
Post by selluwud on Jul 23, 2020 17:08:22 GMT
Crazy man, this must be the cure. Let'er rip. I’m trying to get in one last buy. Hoping for mid $13s. If you waited, your price is even better now for a buy. |
|
|
|
Post by JHam on Jul 23, 2020 17:26:20 GMT
I’m trying to get in one last buy. Hoping for mid $13s. If you waited, your price is even better now for a buy. I did wait. Haven’t bought since my initial buys. Averaged at $12.17 and now hoping it hangs around the $11s or lower, until I can average down. |
|
|
|
Post by JHam on Jul 24, 2020 21:47:53 GMT
|
|
|
|
Post by JHam on Jul 25, 2020 6:38:03 GMT
NurOwn was statistically significant in reduction of pro-inflammatory cytokines in the lungs. Their approach is different than INMB’s as they’re using Mesenchymal stem cells (MSC-NTF), but very encouraging to see an improvement in COVID-19-related ARDS when tackling inflammation. While both BCLI and INMB target cytokine/neuroinflammation I prefer INMB’s approach. BCLI is to increase the amount of NTFs and micro-RNA 132, but still has the issue of not blocking "bad" soluble-TNF (sTNF). I think that if BCLI can get a clinical response in mice by targeting inflammation while not blocking sTNF, then INMB should show good results when doing both. |
|
|
|
Post by JHam on Jul 25, 2020 7:18:24 GMT
Here's a report I just dug up from 2018 on the long term expenditures for Alzheimer's: www.prnewswire.com/news-releases/new-alzheimers-association-report-reveals-sharp-increases-in-alzheimers-prevalence-deaths-and-cost-of-care-300616178.htmlNew Alzheimer's Association Report Reveals Sharp Increases in Alzheimer's Prevalence, Deaths and Cost of CareAnd here is my breakdown: ・$277B : Total cost to care for individuals living with Alzheimer's or other dementias in 2018 (an increase of $20B year over year) ・$1.1T: Projected cost of care for AD patients in 2050 (trillion with a "T") ・$7.9T: Cost savings over the lifetime of all Americans living today with early diagnosis during the MCI (mild cognitive impairment) stage of disease *US numbers only$170M: Current market value of $INMB, the company with some of the most encouraging AD early data ever reported. |
|
|
|
Post by selluwud on Jul 27, 2020 11:19:25 GMT
|
|
|
|
Post by JHam on Jul 27, 2020 12:11:20 GMT
Yep. I posted it a few posts above. It's good. Nothing that we didn't already know, but he does a good job communicating to the general public INMB's approach to fighting COVID. |
|
